

MEMORANDUM

TO: Male-specific Coliphage Committee Members

FROM: Ken B. Moore, Executive Director *Ken B. Moore*

DATE: February 3, 2017

RE: 2016-2017 Committee Charges

This memorandum is to confirm your appointment by the Conference Executive Board Chairman to the Male-specific Coliphage Committee. Patti Fowler will serve as Committee Chair.

1. Proposal 15-102 Guidance Document. The original subcommittee that drafted the proposal is tasked to develop a guidance document for the use of MSC. The draft will be presented to the Executive Board in March for approval. This Subcommittee is being established as a Committee
2. Other Items for Committee Discussion Prior to Development of Guidance
 - Inclusion of MSC guidance into Guidance Document “Determining Appropriately Sized Prohibited Areas Associated with Wastewater Treatment Plants” Committee has agreed this approach is more practical than creating a separate guidance document on MSC.
 - The more appropriate placement of the 50msc/100g language would be in the microbiological standard section of Chapter IV. (Addressed in proposed charges)
 - Clarification of which conditional classification is appropriate for MSC use. (Addressed in proposed charges)
 - The language of Proposal 13-118 provides a rationale for 1000 to 1 but does not include guidance for other classifications to be used for areas adjacent to WWTP.
 - All of the Public Health Explanation and Guidance Document language should be harmonized in the NSSP Guide to make sure the language is consistent.

If you are unable to participate in the activities of this Committee, please contact us at 803-788-7559 or issc@issc.org. Thank you for your interest and support of the ISSC and we look forward to working with you.

/ccm

Male-specific Coliphage Committee:

2016-2017	Name	Email Address
Chair:		
	Patti Fowler, SE Regulatory	patti.fowler2292@gmail.com
Members:		
	Greg Goblick, FDA	Gregory.goblick@fda.hhs.gov
	Tom Howell, NE Industry	tlhowell@spinneycreek.com
	Kohl Kanwit, NE Regulatory	Kohl.kanwit@maine.gov
	Jeff Kennedy, NE Regulatory	jeff.kennedy@state.ma.us
	Chris Roberts, FC	christopher.roberts@ec.gc.ca
Advisors:	Kevin Calci, FDA	kevin.calci@fda.hhs.gov
	Bill Burkhardt, FDA	william.burkhardt@fda.hhs.gov
	Quentin Forrest, FDA	James.forrest@fda.hhs.gov